ARTICLE | Clinical News
SU101 platelet-derived growth factor receptor inhibitor: SUGN enrolling patients who have had surgery or radiation thereapy and chemotherapy
September 21, 1998 7:00 AM UTC
Sugen Inc. (SUGN), Redwood City, Calif. Product: SU101 platelet-derived growth factor receptor inhibitor Indication: Treat non-small cell lung cancer Status: SUGN will enroll up to 30 patients who hav...